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ABSTRACT
The cyclic dinucleotide 2=,3=-cGAMP can bind the adaptor protein STING (stimulator of interferon [IFN] genes) to activate the
production of type I IFNs and proinflammatory cytokines. We found that cGAMP added to the culture medium could suppress
the replication of the hepatitis C virus (HCV) genotype 1b strain Con1 subgenomic replicon in human hepatoma cells. Knock-
down of STING expression diminished the inhibitory effect on replicon replication, while overexpression of STING enhanced
the inhibitory effects of cGAMP. The addition of cGAMP into 1b/Con1 replicon cells significantly increased the expression of
type I IFNs and antiviral interferon-stimulated genes. Unexpectedly, replication of the genotype 2a JFH1 replicon and infectious
JFH1 virus was less sensitive to the inhibitory effect of cGAMP than was that of 1b/Con1 replicon. Using chimeric replicons, 2a
NS4B was identified to confer resistance to cGAMP. Transient expression of 2a NS4B resulted in a pronounced inhibitory effect
on STING-mediated beta IFN (IFN-) reporter activation compared to that of 1b NS4B. 2a NS4B was found to suppress STING
accumulation in a dose-dependent manner. The predicted transmembrane domain of 2a NS4B was required to inhibit STING
accumulation. These results demonstrate a novel genotype-specific inhibition of the STING-mediated host antiviral immune re-
sponse.
IMPORTANCE
The cyclic dinucleotide cGAMPwas found to potently inhibit the replication of HCV genotype 1b Con1 replicon but was less
effective for the 2a/JFH1 replicon and infectious JFH1 virus. The predicted transmembrane domain in 2a NS4B was shown to be
responsible for the decreased sensitivity to cGAMP. The N terminus of NS4B has been reported to suppress STING-mediated
signaling by disrupting the interaction of STING and TBK1 and/or MAVS.We show that 2a/JFH1 NS4B has an additional mech-
anism to evade STING signaling through suppressing STING accumulation.
Hepatitis C virus (HCV) infects approximately 170 millionpeople worldwide, leading to liver diseases, such as cirrhosis
and hepatocellular carcinoma (1, 2). HCV can be classified into
seven major genotypes and over 67 subtypes (3). Intense efforts
over the past 20 years to understand the requirements for HCV
replication have contributed to the development of several direct-
acting antivirals (DAAs) that can cure genotype 1 HCV infection
at a significant rate (4). However, differences exist among the var-
ious genotypes that could impact therapy (5–8). More research is
needed to better understand HCV replication and to effectively
inhibit infection by all genotypes.
HCV is an enveloped positive-strand RNA virus in the Flavi-
viridae family. The HCV genome is of approximate 9.6 kb in
length and encodes a single open reading frame flanked by 5= and
3= untranslated regions (UTRs). The internal ribosome entry site
(IRES) recruits ribosomes to translate viral RNA, producing a
single polypeptide that is co- and posttranslationally processed
into structural proteins (Core, E1, and E2) and nonstructural pro-
teins (p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B) by viral and
cellular proteases (9, 10). All HCV proteins are likely multifunc-
tional, and Core, NS3, NS4B, NS5A, and NS5B have all been re-
ported tomodulate cellular responses to viral infection in addition
to acting on viral RNA replication (10, 11).
HCV infection can activate the production of type I interferons
(IFNs), which can result in the clearance of viral infection (12, 13).
IFNs bind to cognate receptors and activate the transcription of
IFN-stimulated genes (ISGs). The ISG-encoded proteins can in-
hibit virus infection bymultiplemechanisms, including suppress-
ing viral mRNA translation and replication and degradation of
viral RNA (14, 15). Given the role of the innate immune response
activated by IFNs, recombinant alpha IFN (IFN-) is a part of the
standard of care to treat HCV (2).
HCV uses several strategies to counter host antiviral immune
response (11). The NS3/4A proteinase can cleave mitochondrial
antiviral-signaling protein (MAVS; also known as IPS-1, VISA,
and Cardif) and the adaptor protein TRIF (TIR-domain-contain-
ing adaptor inducing IFN-) to abrogate RIG-I- and Toll-like
receptor 3 (TLR3)-mediated innate immune signaling pathways
(16–18). NS4B can interact with STING (stimulator of interferon
gene, also known as MITA, MPYS, ERIS, and TMEM173) and
disrupt the interaction of STING and downstream signaling effec-
tors to block host antiviral immune responses (19, 20). The bal-
ance between activation and blockade of the immune response
could be the key determinant for the outcome of HCV infection.
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HCV NS4B can induce membrane rearrangements that serves
as a scaffold for the viral replicase complex formation (10). NS4B
consists of the N-terminal A domain (amino acids [aa] 1 to 79), a
predicted transmembrane B domain (aa 80 to 191), and a C-ter-
minal C domain (aa 192 to 261). The A domain has been reported
to inhibit STING-mediated IFN- activation (19) and is involved
in virus production (21). The B domain consists of four predicted
transmembrane helices that regulate the replication of HCV ge-
nome and virus production (22). The C domain interacts with
NS4B itself, NS3, and the viral RNA to regulate RNA replication as
well as virus production (23–25).
Cyclic dinucleotides c-di-GMP and c-di-AMP produced by
bacteria are strong elicitors of host type I IFN production (26, 27)
by binding to the adaptor protein STING (28). Recently,mamma-
lian cells have been reported to express the enzyme cGAS (cyclic
GMP-AMP synthase) to produce the 2=,3=-cyclic GMP-AMP
(here abbreviated as cGAMP) that can activate type I IFN produc-
tion (29–34). Although transfection and permeabilization meth-
ods are typically used to deliver the cyclic dinucleotides into cells,
cGAMP can be added to the cell culturemedium to activate IFN-
production in human monocyte THP1 cells (35). In addition,
cGAMP can traffic between cells through the gap junctions to
transmit antiviral responses between cells (36). These observa-
tions suggest that cGAMP could be potentially developed as an
innate immune modulator to control viral infection.
We found that cGAMP added to the culture medium of
Huh7.5 cells inhibited the genotype 1b Con1 replicon replication
via the cGAMP-STINGpathway.However, cGAMPwas less effec-
tive in suppressing the genotype 2a JFH1 replicon replication than
that of the 1b/Con1 strain. The 2a/JFH1 NS4B was found to sup-
press STING accumulation and confer resistance to cGAMP. The
inhibitory effect of 2a NS4B on STING accumulation was primar-
ily mapped to the B domain, suggesting that 2a NS4B hasmultiple
mechanisms to abrogate STING-mediated antiviral immune re-
sponse.
MATERIALS AND METHODS
Cell culture. The human hepatoma cell line Huh7.5 (37), human embry-
onic kidney (HEK) 293T cells (ATCC), and 293-MSR cells (Invitrogen)
were maintained in Dulbecco’s modified Eagle’s medium (DMEM) sup-
plemented with 10% heat-inactivated fetal bovine serum (FBS) at 37°C in
a 5%CO2 incubator.Huh7.5 stable cell lines harboring replicons 1b/Con1
(pFKI389/NS3-3=/WT) and 1b/Con1-RLuc were cultured in DMEM-
10%FBS containing 0.5mg/mlG418 (Invitrogen) as described previously
(38).
Cyclic dinucleotides. Cyclic di-GMP (c-di-GMP) was from Invivo-
gen. 2=,3=-Cyclic GMP-AMP (cGAMP) was synthesized with recombi-
nant human cGAS catalytic domain using ATP and GTP substrates in the
presence of salmon spermDNA as described by Li et al. (35). cGAMPwas
purified by ultrafiltration and Q-Sepharose ion-exchange chromatogra-
phy and eluted with a gradient of NH4HCO3. Purified cGAMPwas lyoph-
ilized to remove NH4HCO3. All cyclic dinucleotides were dissolved in
double-distilled water (ddH2O) at final concentration of 2 or 5 mg/ml.
Plasmid constructions.Plasmid Luc-2a/JFH1 (22) served as the back-
bone to construct chimeric replicons using overlapping PCR. J1/C1-
NS4B1b was made by replacing the NS4B coding sequence with that of
1b/Con1 NS4B. Chimeric replicons J1/C1-A1b, J1/C1-B1b, and J1/C1-C1b
were made by replacement of the sequence coding for the N-terminal 79
codons, predicted transmembrane domain (codons 80 to191), and C-ter-
minal domain (codons 192 to 261) of JFH1 NS4B, respectively, with the
sequence from that of 1b/Con1. J1/GND was a replicon construct con-
taining a mutation in the catalytic residues of NS5B (22). Plasmids
pcDNA-1bNS4B and pcDNA-2aNS4B with a C-terminal hemagglutinin
(HA) tag were constructed by PCR amplification and inserted into NheI/
XhoI of pcDNA3.1. The pcDNA-STING with a Flag tag was previously
described (39). For transient expression, chimeric NS4Bs, 2a/1b-A, 2a/
1b-B, 2a/1b-C, 2a/1b-B(1-2), 2a/1b-B(3-4), and 1b/2a-B, were amplified
by fusion PCR and constructed in the pcDNA3.1 vector.
Transient HCV replicon assay. Plasmids containing the wild type
(WT)or theGDDmutant ofHCV1b/Con1Renilla luciferase (1b/Con1-
RLuc) replicon were linearized with ScaI while the 2a/JFH1-Luc replicon,
chimeric replicons, and JFH1 full-length infectious cDNA clone were lin-
earized with XbaI and then treated with mung bean nuclease to generate
DNA with blunt ends (NEB). In vitro transcription used the AmpliScribe
T7-Flash transcription kit (Epicentre Biotechnologies) with 1 g of lin-
earizedDNAas the template. After a 2-h incubation at 37°C, the transcrip-
tion reaction mixtures were treated with RNase-free DNase I for 30 min,
extracted with a 1:1 phenol-chloroform mixture, and precipitated with
ethanol. RNA pellets were washed with 75% ethanol, dried, and then
dissolved in H2O. The RNA concentration was determined by spectro-
photometry. The integrity and concentration were confirmed by agarose
gel electrophoresis.
HCV replicon RNA was introduced into Huh7.5 cells by electropora-
tion of trypsinized Huh7.5 cells washed with ice-cold Cytomix (120 mM
KCl, 0.15 mM CaCl2, 10 mM K2HPO4-KH2PO4, 25 mM HEPES, 2 mM
EGTA, 5mMMgCl2; pH7.6) and suspended at 2 10
6 cells/ml. TheRNA
and cells were added to a cuvettewith a 2-mmgap andpulsed at 270V, 960
F, with a Gene Pulser (Bio-Rad). Electroporated cells were suspended in
complete medium and seeded in a 96-well plate or a 24-well plate at 1.5
104 and 5  104 cells/well, respectively. The medium was replaced with
complete medium containing indicated concentrations of cyclic dinucle-
otides and incubated for 48 h or 72 h. Luciferase expressed from the
1b/Con1 replicon-harboring Huh7.5 cells was measured using the Dual-
Glo luciferase reporter assay (Promega) in a plate reader (BioTek). The
WST-1 cell proliferation assay was performed according to the manufac-
turer’s instructions (Clontech).
HCV2a/JFH1 virus assay and real-time quantitative RT-PCR (qRT-
PCR). 2a/JFH1 virus (22) infection ofHuh7.5 cells (5104 cells/well) was
performed at a multiplicity of infection (MOI) of 0.01. The cells were
infected with virus for 4 h and then washed with complete medium and
treated with cGAMP for an additional 48 h. Total RNAwas isolated using
theTRIzol reagent (Invitrogen) according to themanufacturer’s protocol,
and specific RNAswere quantified by real-time reverse transcription-PCR
(RT-PCR) using the appropriate primers listed in Table 1. Briefly, 1g of
total RNA was reverse transcribed into cDNA using Moloney murine
leukemia virus (M-MuLV) (NEB) and 4M9-nucleotide (9-nt) random
primer mix. Real-time PCR was performed with the Bio-Rad IQ SYBR
green kit (Bio-Rad). The sampleswere heated to 95°C for 10min, followed
by 45 cycles of PCR of 15 s at 95°C, 20 s at 60°C, and 30 s at 72°C. The
mRNA levels were normalized to the glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) level, and the fold or percent change of RNA was
compared to that of mock-treated controls as described by Livak and
Schmittgen (40).
Western blot assays.Huh7.5 cells were seeded onto a 24-well plate at
a density of 5 104/well and treated with cyclic dinucleotides for 48 or 72
h prior to lysis with radioimmunoprecipitation assay (RIPA) buffer con-
taining 50 mM Tris-Cl, pH 7.5, 150 mMNaCl, 1% NP-40, and a cocktail
of proteinase inhibitors (Roche). The lysates were clarified by centrifuga-
tion at 13,000 rpm for 30 min, and equal amounts of total protein were
separated by 10% SDS-PAGE and transferred to a polyvinylidene difluo-
ride (PVDF)membrane forWestern blot assays. The primarymonoclonal
antibodies to detect NS5A and -actin and the goat anti-mouse IgG cou-
pled with horseradish peroxidase (HRP) were from Santa Cruz Biotech.
Mouse anti-Flag monoclonal antibody and rat anti-HA antibody were
from Sigma and Roche, respectively. Human STING, TBK1, and IRF3
antibodies were from Cell Signaling. Mouse antiubiquitin monoclonal
antibody and mouse anti-human -tubulin antibody were from Santa
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Cruz Biotech. Western blot signals were detected with ECL prime detec-
tion reagent (GE Healthcare) and quantified using the ChemiDoc system
and software (Bio-Rad).
Combination of cGAMPwithDAAs onHCV 1b/Con1 replicon rep-
lication. Increasing concentrations of direct-actingHCVNS5B inhibitors
sofosbuvir (a nucleotide analog; kind gift of Alios Biopharma) and NS5A
inhibitor daclatasvir (Selleckchem) were added along with different doses
of cGAMP to Huh7.5 cells harboring the 1b/Con1-RLuc replicon, and
Renilla luciferase activity was determined at 48 h posttreatment. The 50%
and 75% effective concentrations (EC50 and EC75, respectively) of each
direct-acting antiviral (DAA) alone or combined with cGAMP were cal-
culated and listed in Table 2. The effect of drug combination was deter-
mined using the Chu-Talalay method. The combination index (CI) at
EC75 was calculated with CompuSyn software.
Knockdown and overexpression of STING. STING knockdown was
performed by transfection of STING-specific small interfering RNA
(siRNA) (Santa Cruz Biotechnology) into Huh7.5 cells harboring 1b/
Con1-RLuc replicon using Lipofectamine RNAiMax (Invitrogen) at a fi-
nal concentration of 40 nM. At 48 h posttransfection, the mRNA level of
STINGwas analyzed using quantitative RT-PCR (qRT-PCR), and protein
level was determined by Western blotting. The siRNA-transfected cells
were then trypsinized and seeded in 96-well plates. cGAMP was added at
indicated concentrations, and the Renilla luciferase activity was deter-
mined at 48 h posttreatment. For cells overexpressing human STING,
1b/Con1 replicon cells were transfected with pcDNA-STING for 48 h and
then treated with cGAMP. After an additional 48 h, luciferase activity was
measured.
IFN- luciferase reporter assays. STING-mediated activation of the
IFN- promoter was performed as described in the work of Yi et al. (39).
293T cells were seeded at 4 104 cells/well for 24 h in 96-well plates prior
to transfection with a mixture of plasmids that can express firefly lucifer-
ase regulated by the IFN- or interferon-stimulated response element
(ISRE) promoter elements (pIFN-FFLuc or pISRE-FFLuc; 30 ng), Renilla
luciferase driven by the constitutive thymidine kinase (TK) promoter
(phRL-TKRen; 2 ng), STING (pcDNA-STING; 10 ng), and various
amounts of pcDNA-NS4B to express NS4B. All transfections were
amended with the empty pcDNA3.1 plasmid to allow equal amounts of
plasmid to be transfected. Transfections were performed with Lipo-
fectamine 2000 (Invitrogen). Firefly and Renilla luciferase activities were
determined using the Dual-Glo luciferase reporter assay (Promega). The
ratio of firefly luciferase to Renilla luciferase activities was normalized to
the level of the vector control and plotted as relative fold induction.
Indirect immunofluorescence assay (IFA). The 1b/Con1-RLuc-har-
boring Huh7.5 cells were seeded on glass coverslips in 6-well plates over-
night and then treated with cGAMP for 48 h. The cells were washed with
phosphate-buffered saline (PBS) and fixed for 15 min in 4% paraformal-
dehyde (in PBS) at room temperature followed by 0.5% Triton X-100
treatment at 4°C for 15 min to permeabilize the cells. The fixed cells were
stained withmonoclonal NS5A antibody and Alexa Fluor 488-conjugated
goat anti-mouse IgG (1:200; Molecular Probes). After three washes with
PBS-Tween (PBST), the coverslips were mounted onto glass slides with
Vectashield (Vector Laboratories) and sealed with clear nail polish. For
theNS4B and STINGcolocalization experiment,Huh7.5 cells were seeded
in glass coverslips in a 6-well plate overnight and then were transfected
with indicated amounts of pcDNA-NS4B or chimeras alongwith pcDNA-
STING for 24 h. The cells were fixed and stained with rat anti-HA and
mouse anti-Flag antibodies following by Alexa 647-conjugated goat anti-
rat IgG antibody and Alexa 488-conjugated goat anti-mouse IgG anti-
body. Immunostained samples were visualized with a Leica SP5 confocal
microscope.
Immunoprecipitation assay. 293T cells were seeded onto 6-well
plates and transfected with pcDNA-STING-Flag (1 g) and pcDNA-
1bNS4B-HA (1 g) by Lipofectamine 2000. After 24 h, the cells were
washed and lysed in RIPA buffer with a cocktail of proteinase inhibitors
(Roche). Cell lysates were clarified by centrifugation at 13,000 rpm for 30
min at 4°C. Immunoprecipitation used either a rat-anti-HA monoclonal
antibody or a mouse anti-Flag monoclonal antibody and protein A/G
magnetic beads (Thermo Scientific) according to themanufacturer’s pro-
tocol. The immunoprecipitated materials were dissolved in 1 Laemmli
buffer and heated at 95°C for 5min prior to separation by SDS-PAGE and
detection via immunoblotting.
Statistical analysis. The data were analyzed using the Student t test.
Data were expressed as an average of triplicates with standard deviation
(error bar), unless stated otherwise. P values of 0.05 were considered
statistically significant.
RESULTS
cGAMP inhibits HCV 1b/Con1 replicon replication. Huh7.5
cells harboring a 1b/Con1 replicon that expresses the Renilla lu-
ciferase (1b/Con1-RLuc) were used to examine whether cGAMP
could inhibitHCV replication. cGAMPwas added into the culture
TABLE 1 Primer pairs used for real-time RT-PCR
Gene
Sequence (5=–3=)
Forward Reverse
GAPDH GAGTCAACGGATTTGGTCGT TGGGATTTCCATTGATGACA
Con1 AGCCATGGCGTTAGTATGAGTGTC ACAAGGCCTTTCGCGACCCAAC
JFH1 AGCCATGGCGTTAGTATGAGTGTC ACAAGGCCTTTCGCAACCCAAC
STING GAGAGCCACCAGAGCACAC CGCACAGTCCTCCAGTAGC
IFN- GTGAGGAAATACTTCCAAAGAATCAC TCTCATGATTTCTGCTCTGACAA
IFN- AGCTGAAGCAGTTCCAGAAG AGTCTCATTCCAGCCAGTGC
TNF- CATCTTCTCAAAATTCGAGTGACAA TGGGAGTAGACAAGGTACAACCC
MxA CCCTTCCCAGAGGCAGCGGG CTGATTGCCCACAGCCACTC
OAS GGTGGTAAAGGGTGGCTCCTC TCTGCAGGTAGGTGCACTCC
PKR CCAGTGATGATTCTCTTGAGAG CCCCAAAGCGTAGAGGTCCA
TABLE 2 Inhibitory constants of DAAs alone and with cGAMP
DAA EC50 EC75
Sofosbuvir (M)
Alone 0.96 1.83
Plus 50 g/ml cGAMP 0.13 0.60
Fold change 7.47 3.04
Combination index 1.02
Daclatasvir (pM)
Alone 14.44 34.92
Plus 50 g/ml cGAMP 1.78 10.45
Fold change 8.08 3.34
Combination index 1.00
Yi et al.
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medium in increasing concentrations, andRenilla luciferase activ-
ity was determined at 48 h posttreatment. cGAMP, but not c-di-
GMP, inhibited luciferase activity from 1b/Con1 in a concentra-
tion-dependent manner. The effective concentration for 50%
reduction (EC50) by cGAMP was 50 g/ml (Fig. 1A). cGAMP
had aminor impact on cell proliferation and viability when added
up to 80 g/ml, as determined by measuring the mitochondrial
dehydrogenase activity using the WST-1 reagent (Fig. 1A). The
50% cytotoxicity concentration (CC50) for cGAMP was in excess
of 400 g/ml (data not shown).
To confirm that cGAMP has inhibitory effects on HCV replica-
tion, we determined the level of 1b/Con1 viral RNA using quantita-
tive RT-PCR. The viral RNA level decreasedwith the increasing con-
centrationsof cGAMPadded to themedium(Fig. 1B).Areduction in
HCV NS5A protein accumulation was also detected via Western
blotting and immunofluorescence assays (Fig. 1C and D).
cGAMP and direct-acting antivirals additively inhibit 1b/
Con1 replicon replication. To examine whether the antiviral ac-
tivity of cGAMP could act in concert with direct-acting antivirals
(DAAs) to inhibit HCV RNA replication, the NS5B polymerase
inhibitor sofosbuvir, a nucleotide analog (41), and daclatasvir, an
NS5A inhibitor (42), were tested in combination with different
concentrations of cGAMP for 48 h. In the presence of 50g/ml of
cGAMP, cells treated with daclatasvir or sofosbuvir decreased the
EC50 by more than 7-fold (Table 2). The combination index (CI)
for cGAMPwith sofosbuvir or daclatasvir was 1.02 or 1 (Table 2),
respectively, suggesting that the inhibitor combinations had an
additive effect. These results demonstrate that cGAMP could en-
hance the inhibitory effects of DAAs on 1b/Con1 replicon repli-
cation.
STING is required for the inhibitory effect of cGAMP.Cyclic
dinucleotides can trigger type I IFNs and proinflammatory re-
sponses through several proteins, including STING, DDX41, and
NLRP3 (26, 43, 44). To determine whether STING is required for
the inhibitory effect of cGAMP,we used siRNA to knock down the
endogenous STING in 1b/Con1 replicon cells and evaluated the
effect of cGAMP on HCV replication. The STING protein level
was only 5% of that of U937 human leukemic monocyte lym-
phoma cells (data not shown) but could be detected in the 1b/
Con1 replicon-harboring Huh7.5 cells (Fig. 2A). The knockdown
by siRNA decreased the STINGmRNA and protein levels by 75%
and 50%, respectively (Fig. 2A). Knockdown of STING increased
1b/Con1 replicon replication by 1.7-fold even without the ex-
ogenous cGAMP (Fig. 2B), suggesting that STING is involved in
restricting 1b/Con1 replication in Huh7.5 cells. The knockdown
of STINGdramatically diminished the inhibitory effect of cGAMP
on 1b/Con1 replicon replication (Fig. 2C).
The effect of STING overexpression on HCV Con1 replicon
replication was also examined. Transfection of pcDNA-STING
plasmid into replicon cells reduced 1b/Con1 RNA level by 35 to
40% even in the absence of cGAMP (Fig. 2D and E). In the pres-
ence of cGAMP, the EC50 was ca. 20g/ml for replicon cells over-
expressing STING, while it was 50 g/ml for cells with endoge-
nous levels of STING (Fig. 2F and 1A). Results from both
knockdown and overexpression of STING demonstrate that
STING mediates the inhibition of HCV 1b/Con1 replicon repli-
cation in Huh7.5 cells.
cGAMP triggers type I IFN and antiviral ISG expression.
STING interacts with TBK1 and IRF3 to promote the phosphor-
ylation of IRF3 that leads to type I interferon production (45). To
examine whether cGAMP could activate the antiviral innate im-
mune response in the Huh7.5 cells harboring the 1b/Con1 repli-
con, the mRNA levels for various IFNs and interferon-stimulated
genes (ISGs) were determined by real-time RT-PCR 48 h after
cGAMP treatment. Relative to the mock-treated cells, the mRNA
levels for IFN-, IFN-, and tumor necrosis factor alpha (TNF-)
FIG 1 cGAMP can inhibit 1b/Con1 replicon replication in Huh7.5 cells. (A) cGAMP suppresses 1b/Con1-RLuc replication. Renilla luciferase, expressed from
the replicon, was measured at 48 h after the addition of either cGAMP or c-di-GMP to the medium. The data were plotted as percent inhibition relative to
mock-treated sample. Cell viability data (WST-1) were added to the same graph by determining the optical density at 450 nm according to the manufacturer’s
protocol. The cells were treated with cGAMP in parallel with those used in the luciferase assay. The data were expressed as an average of triplicates with standard
deviation (error bar). (B) Viral RNA level in replicon-harboring cells in the presence of increasing cGAMP concentrations. The viral RNA was quantified by
real-time RT-PCR. The results were normalized to the level of GAPDH mRNA. (C) Western blot analysis of NS5A level in cGAMP-treated 1b/Con1-RLuc
replicon cells. The NS5A was detected with mouse monoclonal anti-NS5A antibody and HRP-conjugated goat anti-mouse IgG. -Actin served as the loading
control. (D) Indirect immunofluorescence analysis of NS5A expression in replicon cells. The replicon cells were treated with cGAMP for 48 h and stained with
mouse anti-NS5A monoclonal antibody and Alexa Fluor 488-conjugated goat anti-mouse antibody. Nuclei were stained with 4=,6-diamidino-2-phenylindole
(blue).
HCV NS4B Suppresses STING Accumulation
January 2016 Volume 90 Number 1 jvi.asm.org 257Journal of Virology
 o
n
 Septem
ber 12, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
were increased by 6-, 12-, and 26-fold, respectively, in cells treated
with 80 g/ml of cGAMP (Fig. 3A). The mRNA levels of antiviral
ISGs MxA and OAS were increased by 6- and 5-fold, respectively,
compared to that of mock-treated samples (Fig. 3B). Notably, the
increase of the cytokines and ISG mRNA levels correlated with a
decrease in HCV 1b/Con1 RNA levels (Fig. 1B and data not
shown). These results suggest that cGAMP activates the host an-
tiviral innate immune response that likely results in the inhibition
of 1b/Con1 replication.
cGAMP is less effective in reducing 2a/JFH1 replicon replica-
tion. Different genotypes of HCV are known to be differentially
sensitive to direct-acting antivirals (6–8). Therefore, we examined
whether cGAMP could inhibit the replication of the genotype 2a
JFH1 replicon. Huh7.5 cells electroporated with 1b/Con1-RLuc
or 2a/JFH1-Luc replicon RNA were treated with increasing con-
centrations of either c-di-GMP or cGAMP for 72 h, and the rep-
lication efficiency was determined. The replication of the 1b/
Con1-RLuc was inhibited by cGAMP with an EC50 of 50 g/ml.
However, cGAMP was not effective in reducing replication of the
2a/JFH1 replicon (Fig. 4A).
We also examined the effects of cyclic dinucleotides onHuh7.5
cells infected with the genotype 2a JFH1 virus. Huh7.5 cells were
infectedwith the virus at amultiplicity of infectivity (MOI) of 0.01
and treated with indicated concentrations of c-di-GMP or
cGAMP for 48 h. The JFH1 viral RNAwas onlymodestly inhibited
in cells treated with 100 g/ml of cGAMP as determined by qRT-
PCR (Fig. 4B). In agreement with the results from 2a/JFH1 repli-
con, these data indicate that the replication of 2a/JFH1 is less sen-
sitive to the effects of cGAMP than that of 1b/Con1.
The 2a/JFH1 NS4B suppresses STING accumulation. HCV
has several strategies to modulate the innate immune responses
(11). For example, NS4B was reported to inhibit the STING-me-
diated type I IFN response (19, 20). We therefore determined the
subcellular distribution of NS4B and STING in cells coexpressing
the two proteins. As shown in Fig. 5A, both 1b and 2a NS4Bs
colocalized with STING in Huh7.5 cells. Furthermore, coimmu-
noprecipitation experiments showed that 1b/Con1 and 2a/JFH1
NS4Bs associated with STING in 293T cells (Fig. 5B). This has led
us to postulate that NS4Bs from 1b/Con1 and 2a/JFH1 have dis-
tinct abilities to inhibit STING-mediated innate immune re-
sponses. To test this hypothesis, the 293T cells were transfected to
express increasing amounts of either 1b or 2a NS4B along with a
fixed amount of STING, IFN-–firefly luciferase reporter, and
TK-Renilla luciferase reporter.While bothNS4Bproteins reduced
firefly luciferase expressed from the IFN- promoter, 2a NS4B
exhibited a more pronounced inhibitory effect than did 1b NS4B
(Fig. 5C). 2a NS4B expressed from 20 ng of transfected plasmid
reduced luciferase activity to background, while the comparable
amount of 1b NS4B decreased luciferase readout by only 15%
(Fig. 5C). A similar result was obtained with a luciferase reporter
driven by an interferon-stimulated response element (ISRE)
(Fig. 5D).
To examine whether NS4B proteins could differentially affect
STING accumulation, 293T cells were transfected with a fixed
FIG 2 Effects of knockdown and overexpression of STING on cGAMP-mediated inhibition of HCV 1b replicon replication. (A) Knockdown of endogenous
STING. The replicon-harboring Huh7.5 cells were transfected with 40 nM human STING siRNA or control siRNA. Forty-eight hours later, the mRNA level of
STINGorGAPDHwas determined by real-timeRT-PCR, and the protein level of STINGor-tubulinwas determined byWestern blotting. (B) Impact of STING
knockdown on HCV 1b/Con1 replicon replication. The Renilla luciferase level in the siRNA-transfected replicon cells was determined at 48 h posttransfection
and plotted as the percentage of control siRNA. The data were plotted as an average of triplicates with standard deviation (error bar). The asterisk denotes a P
value of0.05. (C) Effects of STING knockdown on the inhibitory effect of 1b/Con1 replicon replication by cGAMP. The replicon cells were treated with siRNA
for 48 h and then treated with cGAMP. Renilla luciferase activity expressed from the replicon was measured at 48 h posttreatment and plotted relative to the
mock-treated sample. The black circles andwhite squares denote cells treated with control siRNA and STING siRNA, respectively. (D)Overexpression of human
STING in replicon-harboringHuh7.5 cells. The replicon cells were transfectedwith pcDNA-STINGplasmid for 48 h. ThemRNA level andprotein level of STING
were determined by quantitative RT-PCR andWestern blotting. (E) Effect of STING overexpression onHCV 1b/Con1 replicon replication. The asterisk denotes
a P value of0.05. (F) Effect of STING overexpression on the inhibitory effect of 1b/Con1 replicon replication by cGAMP. The black circles and white squares
denote cells transfected with pcDNA vector and pcDNA-STING plasmid, respectively.
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amount of STING plasmid along with increasing concentrations
of either 1b or 2a NS4B. As seen in Fig. 5E (right), 2a NS4B sup-
pressed STING accumulation in a dose-dependent manner. In
contrast, 1b NS4B had only a modest effect on the STING accu-
mulation (Fig. 5E, left). Similar results were obtained from
Huh7.5 cells (Fig. 5F). To exclude the possibility that themRNAof
2aNS4Bmightmediate the inhibitory effect, we introduced a stop
codon at amino acid position 22 of NS4B, named 2a NS4B/fs. The
2a NS4B/fs mutant dramatically diminished the inhibitory effect
(Fig. 5G). Both WT and 2a NS4B/fs had only modest effects on
IRF3 accumulation (Fig. 5G). This result suggests that 2a NS4B
protein, instead of mRNA, is required to suppress STING accu-
mulation.
Next, we sought to examine whether 2aNS4B could inhibit the
endogenous STING accumulation using HEK293 cells, which ex-
press relatively lower levels of endogenous STING (46). Increasing
expression of 2a NS4B, but not 1b NS4B, suppressed the endoge-
nous STING accumulation, while TBK1 and IRF3 levels were only
modestly affected (Fig. 5H). A similar result was observed in
Huh7.5 cells (Fig. 5I). Since STING is required for the inhibition
of 1b/Con1 replicon replication by cGAMP, the downregulation
of STING accumulation by 2a NS4B could account for the de-
creased sensitivity to cGAMP by the 2a/JFH1 replicon.
2a/JFH1 NS4B confers resistance to the inhibitory effect of
cGAMP. We used chimeric replicons to determine whether 2a/
JFH1NS4B could confer resistance to cGAMP. The J1/C1-NS4B1b
chimeric replicon had the 2a/JFH1 NS4B coding sequence re-
placed with the comparable sequence from 1b/Con1 NS4B (Fig.
6A). The replication of J1/C1-NS4B1b at 72 h postelectroporation
was examined relative to the replication-competent JFH1 replicon
and the J1/GND replicon, which encodes a catalytically inactive
NS5B (Fig. 6B). J1/C1-NS4B1b replicated at levels about 5- to 10-
fold lower than those of the 2a/JFH1 replicon, consistent with a
previous report (22). In the presence of 75 g/ml cGAMP, the
luciferase expression from the J1/C1-NS4B1b chimera decreased
by 68% to the level of the mock-treated control (Fig. 6C). The
replication of the 1b/Con1 replicon was decreased to near back-
ground. A similar inhibitory effect was observed at 72 h posttreat-
ment (data not shown). This result demonstrates that the NS4B
proteins from the two different HCV genotypes can affect the
inhibition by cGAMP.
NS4B contains three domains (Fig. 6A). To determine the do-
mains in NS4B that confer the resistance to cGAMP, we used
chimeric replicons in 2a/JFH1 backbone that had exchanges of the
three 2a NS4B domains with those of 1b NS4B (Fig. 6A). In the
absence of cGAMP, the replication level of J1/C1-A1b, which has
the A domain of 2a NS4B replaced with that of 1b NS4B, was
similar to that of J1/C1-C1b, which has the C domain of 2a NS4B
FIG 3 cGAMP triggers the expression of type I IFNs and ISGs in 1b/Con1
replicon-harboring Huh7.5 cells. (A) Effects of cGAMP on IFN-, IFN-, and
TNF-mRNA expression. Approximately 5 104 replicon cells were seeded
on a 24-well plate and treated with cGAMP for 48 h. Total RNA was isolated
and reverse transcribed into cDNA with random primers. cDNA was quanti-
fied by real-time PCR with the specific primer pairs listed in Table 1. The data
were plotted as fold change from triplicate compared to that of mock-treated
sample. (B) Effects of cGAMP on ISG MxA, OAS, and PKR mRNA levels.
FIG 4 Effects of cyclic dinucleotides on genotype 2a JFH1 replicon and infec-
tious virus replication. (A) Effects of cyclic dinucleotides on 2a/JFH1 replicon
replication. Huh7.5 cells were electroporated with in vitro-transcribed repli-
con RNA and seeded onto a 96-well plate. After 24 h, themediumwas changed
and the cells were treated with indicated concentrations of cyclic dinucleotides
for an additional 48 h. Luciferase activity was measured, and the data were
plotted relative to the mock-treated control. The data represent two indepen-
dent experiments, each with triplicate samples. The open circle and triangle
represent c-di-GMP and cGAMP, respectively. The dashed line represents the
result from 1b/Con1 replicon, which served as the control. (B) Effects of cyclic
dinucleotides on JFH1 infectious virus replication. Huh7.5 cells were infected
with JFH1 virus at an MOI of 0.01 FFU/cell for 4 h and then treated with
indicated concentrations of cyclic dinucleotides. Viral RNA was quantified by
real-time RT-PCR 48 h posttransfection and normalized to GAPDH. The
data represent the percentage of virus replication compared to mock-
treated sample.
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replaced with that of 1b NS4B (Fig. 6A and B). J1/C1-B1b, which
has the B domain from 1b/Con1 NS4B, replicated to levels about
10-fold lower than those of 2a/JFH1 (Fig. 6B). In the presence of
75 g/ml of cGAMP, replication of J1/C1-B1b was significantly
inhibited, similarly to that of J1/C1-NS4B1b, while J1/C1-A1b was
unaffected compared to the mock-treated control (Fig. 6C). The
replication of J1/C1-C1b was also inhibited by 53%, suggesting
that the B and C domains of 2a NS4B contribute to the resistance
to cGAMP.
The B domain of 2a NS4B is required to inhibit STING accu-
mulation. To identify the domain(s) in 2a NS4B required to in-
hibit STING accumulation, the chimeric NS4Bs were constructed
in the pcDNAvector (Fig. 7A). Expression of the chimeric 2a/1b-B
protein (2a NS4B with the B domain from 1b) abrogated the in-
hibitory effect of 2a NS4B on STING, while 2a/1b-A protein (2a
NS4B with the A domain from 1b) decreased STING accumula-
tion to a level similar to that of WT 2a NS4B (Fig. 7B), suggesting
that the B domain primarily contributes to the inhibition of
FIG 5 2a NS4B can downregulate STING accumulation. (A) Colocalization of NS4B with STING in Huh7.5 cells. The cells were transfected with STING-Flag
plasmid along with equal amounts of either 1bNS4B-HA or 2aNS4B-HA plasmid. After 30 h, the cells were processed for fluorescencemicroscopy with anti-HA
antibody (NS4B; red) and anti-Flag antibody (STING; green). The fluorescence was visualized with a Leica SP5 confocal microscope. (B) Immunoprecipitation
of NS4B and STING in 293T cells. The cells were transfected with equal amounts of the empty vector or STING-Flag and either 1b NS4B-HA or 2a NS4B-HA
plasmid. The cell lysate was immunoprecipitated with mouse anti-Flag monoclonal antibody followed by immunoblotting with rat anti-HA antibody. The
STING and NS4B protein levels in cell lysates were probed with anti-Flag and anti-HA antibodies. (C) Effects of transient expression of NS4B proteins from 1b
and 2a on STING-mediated IFN- reporter expression in 293T cells. The cells were transfected with constant amounts of STING-Flag, IFN- firefly luciferase
(IFN--FLuc) reporter, and TK-Renilla luciferase (TK-RLuc) reporter together with indicated amounts of either 1b NS4B-HA or 2a NS4B-HA. The FLuc and
RLuc activities were measured, and the ratio of FLuc to RLuc was determined. The data were plotted as fold induction for the IFN promoter activity in the
presence of STING with or without NS4B protein. (D) Effects of NS4B expression on ISRE reporter expression. The experiment was performed as in panel C
except that the transfection mixture included ISRE-Luc reporter. (E) Western blot analysis of STING accumulation in the presence of NS4B in 293T cells. The
cells were transfected with fixed amount of STING-Flag along with increasing concentrations of either 1b NS4B-HA or 2a NS4B-HA. Cell lysate was
subjected to SDS-PAGE followed by Western blotting with Flag- and HA-specific antibodies. -Tubulin served as a loading control. The STING level was
quantified and normalized to -tubulin using ImageQuant software. (F) Effects of NS4B expression on STING accumulation in Huh7.5 cells. The
experiment was performed as in panel E except that Huh7.5 cells were transfected. (G) Effects of 2a NS4B/fs mutant expression on STING and IRF3
accumulation in HEK293T cells. (H) Effects of NS4B expression on endogenous STING accumulation in 293 cells. The cells were transfected with
increasing concentrations of NS4B, and the endogenous levels of STING, TBK1, and IRF3 were examined by Western blotting. (I) Effects of NS4B on
endogenous STING accumulation in Huh7.5 cells.
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STING accumulation. 2a/1b-C also partially suppressed STING
accumulation but less efficiently than did WT 2a NS4B. Compa-
rable results were observed in 293T cells (Fig. 7C).
TheNS4BBdomain consists of four predicted transmembrane
helices. To furthermap the elements required for the inhibition of
STING accumulation, the sequences that form helices 1 and 2 and
helices 3 and 4 of 2a/1b-B NS4B were replaced with those from 2a
NS4B and named 2a/1b-B(1-2) or 2a/1b-B(3-4) NS4B, respec-
tively (Fig. 7A).While 2a/1b-BNS4B did not inhibit STING accu-
mulation, 2a/1b-B(1-2) and 2a/1b-B(3-4) proteins could partially
restore the ability to suppress STING accumulation (Fig. 7D).
This result suggests that transmembrane domain helices 1 and 2
and helices 3 and 4 of 2aNS4B both contribute to the inhibition of
STING, presumably through the helix-helix interactions in the
transmembrane domain (47). Next, we replaced the B domain of
1b NS4B with the 2a counterpart (named 1b/2a-B [Fig. 7A]) to
test whether the B domain of 2a NS4B was sufficient to enable 1b
NS4B to suppress STINGaccumulation. The 1bNS4B protein had
minor effects on STING accumulation as expected, while the chi-
meric 1b/2a-B protein inhibited STING accumulation to a level
similar to that of 2a NS4B (Fig. 7E), indicating that the B domain
of NS4B is primarily responsible for the distinct regulation of
STING accumulation.
To further determine whether the B domain of 2a NS4B could
affect the accumulation of endogenous STING, 293 cells were
transfected with increasing concentrations of either 2a NS4B, 2a/
1b-B, or 1b NS4B. The endogenous levels of STING and down-
stream signaling molecules TBK1 and IRF3 were examined by
Western blotting. 2a NS4B could suppress STING but had only
modest effects on TBK1 and IRF3 accumulation, while 2a/1b-B
dramatically decreased the inhibitory effect on STING accumula-
tion (Fig. 7F).
To confirm these results, chimeric constructs were tested in the
STING-mediated IFN- luciferase reporter assay in 293T cells. As
expected, 2a NS4B inhibited IFN- promoter activation more ef-
ficiently than 1b NS4B (Fig. 7F). The chimeric protein 2a/1b-B
dramatically decreased the ability of 2a NS4B to inhibit IFN-
reporter expression (Fig. 7F) and exhibited an inhibitory effect
similar to that of 1b NS4B. In addition, the 1b/2a-B chimera ex-
hibited the same inhibitory effect as that of 2a NS4B (Fig. 7G).
Altogether, these results demonstrate that the B domain of 2a
NS4B primarily contributes to the genotype-specific suppression
of STING accumulation.
DISCUSSION
In this work, we found that cGAMP could inhibit HCV genotype
1b/Con1 replicon replication in Huh7.5 cells through activation
of STING-mediated type I IFNs and cytokine production. cGAMP
was less effective in inhibiting the replication of the genotype 2a
JFH1 replicon or the infectious JFH1 virus. The distinct effects of
cGAMP are at least partially due to the different abilities of 1b and
2a NS4Bs to inhibit STING signaling through suppressing STING
accumulation. The predicted transmembrane domain of 2aNS4B,
the B domain, was primarily responsible for the resistance to
cGAMP and suppression of STING accumulation.
cGAS can bind DNA from pathogens such as herpes simplex
virus and HIV (cDNA) and produce cGAMP to trigger the host
innate immune response (48, 49). However, cGAS cannot sense
and bind RNA, and the antiviral role of cGAS and its product
cGAMP for RNA viruses is still not clear. Nevertheless, overex-
pression of cGAS could regulate the replication of an RNA virus,
WestNile virus (50).Our results demonstrate that the cGASprod-
uct cGAMP could directly inhibit HCV genotype 1b Con1 repli-
con replication when it was added into the cell medium. The in-
hibitory effect was not observed with bacterial second messenger
c-di-GMP, likely due to c-di-GMP not being able to enter cells.
cGAMP has been reported to bind the recombinant STING pro-
tein with a Kd (dissociation constant) of 5 to 60 nM while c-di-
GMPbound to STINGwith aKdof 1 to 5M(34, 35). The distinct
phosphodiester linkages between the dinucleotides could also af-
FIG 6 NS4B contributes to the distinct sensitivities of 1b/Con1 and 2a/JFH1
replicons to cGAMP. (A) Schematic diagram of chimeric replicons. 2a/JFH1-
Luc replicon contains HCV 5= UTR with its IRES directing firefly luciferase
expression and the NS3-5B protein-coding region under the control of the
encephalomyocarditis virus (EMCV) IRES. J1/C1-NS4B1b is a chimeric repli-
con that contains full-length 1b/Con1 NS4B in the 2a/JFH1-Luc backbone.
J1/C1-A1b, J1/C1-B1b, and J1/C1-C1b represent the chimeric replicons in
which the A, B, and C domains of 2a NS4B were replaced with those of 1b
NS4B. (B) Replication of parental and chimeric replicons in Huh7.5 cells.
Huh7.5 cells were electroporated with the indicated replicon RNAs. At 48 h
posttransfection, the luciferase activity was measured and plotted as fold in-
duction relative to the catalytic site mutant GND or GDD. (C) Effects of
cGAMP on the chimeric replicon replication in Huh7.5 cells. Huh7.5 cells
were seeded onto a 96-well plate and electroporated with replicon RNA for 24
h. The cells were thenmock treated or treated with 75g/ml of cGAMP for 48
h, and the luciferase activity was determined. The data were expressed as an
average from triplicates and plotted as a percentage of the mock-treated sam-
ples. The statistical analysis of the inhibitory effects relative to the 2a/JFH1
replicon was calculated using the Student t test. The asterisk denotes a P value
of0.05.
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fect binding to STING as well as their sensitivities to phosphodi-
esterases (31, 32, 34).
STING is a key player in the response to the DNA and RNA
virus-activated signaling pathway (51, 52). Similarly to cGAS,
STING cannot directly bind RNA in vitro, raising questions as to
how STING can recognize an RNA virus. Since STING can bind
MAVS, TBK1, and IRF3, the downstream molecules of the RNA
sensors RIG-I and MDA5 (45, 51, 53), it is possible that STING
triggers the innate immune response through cross talk with RNA
sensors. STING has been reported to restrict the replication of a
number of RNA viruses, including Japanese encephalitis virus,
dengue virus, hepatitis C virus, and coronavirus (19, 54–56). Our
results confirm that STING can restrict HCV replication in
Huh7.5 cells. Knockdownof STINGenhancedHCV1b/Con1 rep-
licon replication, while its overexpression inhibited HCV replica-
tion inHuh7.5 cells (Fig. 2B and E).Huh7.5 cells contain amutant
RIG-I protein and a defective RIG-I signaling pathway (57); there-
fore, the restriction of HCV replication by STING is likely inde-
pendent of RIG-I.
The inhibition ofHCV2a/JFH1 replication by cGAMPwas not
as pronounced as that of 1b/Con1. Results with chimeric replicons
suggest that the NS4B protein contributes to the distinct inhibi-
tion by cGAMP through suppressing STING accumulation.
NS4Bs from different genotypes thus have different capacities to
FIG7 The inhibitory effect ofNS4B on STING accumulation is primarilymapped to the B domain. (A) Schematic representation of parental and chimericNS4B
constructs. A, B, and C denote the three domains of the NS4B protein. (B) Effects of NS4B chimeric constructs on STING accumulation. Huh7.5 cells were
transfected with fixed amounts of STING and increasing concentrations of NS4B chimeras for 30 h. The cell lysate was separated by SDS-PAGE followed by
Western blotting. Tubulin level served as a loading control. The relative level of STINGwas quantified and normalized to-tubulinwithChemiDoc software. (C)
Effects of NS4B subdomain chimeras on STING accumulation. The experiment was performed as in panel B, except that 293T cells were transfected. (D) Effects
of NS4B domain B helices on STING accumulation in 293T cells. (E) Effect of 1b/2a-B NS4B expression on STING accumulation. (F) Effects of NS4Bs and
chimera 2a/1b-B on the endogenous STING accumulation in 293 cells. 293 cells were transfected with increasing concentrations of either 2a NS4B, 1b NS4B, or
2a/1b-B plasmid. The endogenous STING, TBK1, and IRF3 levels were detected byWestern blotting. (G) Effects ofNS4B chimera on the inhibition of IFN--Luc
reporter expression. 293T cells were transfected with fixed amounts of STING, IFN--Luc, and TK-Luc along with increasing concentrations of either NS4B or
its chimeras. After 24 h, luciferase activity was determined and the data were plotted as IFN- fold induction relative to the cells treatedwith 1b/Con1NS4b. Data
were expressed as an average of triplicates with standard deviation of the mean. (H) Effects of 1b/2a-B on the IFN- reporter expression. The asterisk denotes a
P value of0.05.
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evade STING-mediated innate immune responses. The ability of
NS4B to inhibit STING accumulation and cGAMP-mediated im-
mune responses could potentially influence the outcome of HCV
infection. Indeed, knockdown of STING expression enhanced 1b/
Con1 replicon replication by 60 to 70% (Fig. 2B). The chimeric
replicons J1/C1-NS4B1b and J1/C1-B1b, which contain full-length
1b/Con1 NS4B and the predicted transmembrane domain of 1b
NS4B, respectively, were more susceptible to the inhibitory effect
of cGAMP and replicated at levels 5- to 10-fold lower than that of
theWT 2a/JFH1 replicon. However, not only is NS4B involved in
membranous web formation, associated with other nonstructural
proteins, NS3, NS5A, and NS5B, to form the replicase complex,
but also it affects virion assembly (21, 25, 58). Therefore, we can-
not conclude that the defect of replication by NS4B chimeric rep-
licon J1/C1-NS4B1b was merely due to the different regulation of
STING accumulation.
RNA viruses have evolved different mechanisms to antagonize
the innate immune response by STING.Dengue virus NS2B/3 can
bind and cleave human STING (54, 59). Nitta et al. (19) and Ding
et al. (20) reported that HCV NS4B can suppress the type I inter-
feron response through disruption of STING interaction with
downstream signaling molecule TBK1 or MAVS (19, 20). How-
ever, they did not observe a decrease of STING accumulation. Our
results with HCV 1b NS4B are consistent with those of Nitta et al.
(19) and Ding et al. (20). However, we observed that 2a NS4B
could antagonize STING-mediated signaling through decreasing
STING accumulation (Fig. 5E and F). Furthermore, we showed
that 2a NS4B suppression of STING accumulation is strictly de-
pendent on the level of STING and NS4B expression (Fig. 5E and
F). Ding et al. (20) have not detected the decrease of STING accu-
mulation by 2a NS4B; this could be due to the large amount of
STING protein expressed or an insufficient amount of NS4B plas-
mid transfected in cells. We note that NS4B from 2a/JFH1 could
account for a significant portion of resistance to cGAMP; how-
ever, it is possible that otherHCVmolecules could also contribute
to resistance through association with NS4B. While HCV NS4B
has different strategies to suppress STING-mediated antiviral sig-
naling, whether STING signaling is activated and whether STING
contributes to the interferon response during HCV infection in
patients remain to be determined.
The inhibitory effect of 2a NS4B was mapped to the B and C
domains that contain, respectively, the predicted transmembrane
domain and the RNA binding domain. The B domain is primarily
responsible for the inhibitory effect. Sequence alignment shows
that NS4Bs of the 7 major genotypes contain 44% identity. How-
ever, NS4Bs from 1b/Con1 and 2a/JFH1 share 72% amino acid
identity. The B domains and C domains of 1b/Con1 and 2a/JFH1
share 77% and 73% amino acid identity, respectively. The argi-
nine residues in the C domain of NS4B have been shown to be
involved in RNA binding (60); however, they are conserved in
different genotypes of HCV, suggesting that RNA binding might
not be primarily responsible for the distinct inhibition of STING
accumulation by NS4Bs. The B domain contains four predicted
transmembrane helices; how this domain contributes to the inhi-
bition of STING accumulation remains to be determined.
Last, we demonstrated that cGAMP added to the cell medium
could enhance antiviral activity through activating IFNs and an-
tiviral ISG production. The use of cGAMP to treat HCV infection
could have advantages from the use of recombinant IFN. First,
cGAMP could trigger the production of multiple subtypes of
IFNs, ISGs, and cytokines, such as TNF- expression (Fig. 3A).
Second, cGAMP can traffic from cell to cell to expand the innate
immune response to neighbor cells (36). Third, cGAMP contains
distinct 2=-5= phosphodiester linkages between the dinucleotides,
which could increase the stability in cells. Patients with genotype 1
HCV infection are themost difficult to cure, and a combination of
cGAMPwith DAAs can enhance the antiviral effect in vitro (Table
2). It may be worthwhile to examine the antiviral effect of cGAMP
and the combined effects of cGAMP and DAAs in treatment of
other viral diseases.
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Correction for Yi et al., “Hepatitis C Virus NS4B Can Suppress
STING Accumulation To Evade Innate Immune Responses”
Guanghui Yi,a Yahong Wen,a Chang Shu,b Qingxia Han,c Kouacou V. Konan,c Pingwei Li,b C. Cheng Kaoa
Department of Molecular and Cellular Biochemistry, Indiana University, Bloomington, Indiana, USAa;
Department of Biochemistry and Biophysics, Texas A&M University, College Station, Texas, USAb; Center for
Immunology and Microbial Disease, Albany Medical College, Albany, New York, USAc
Volume 90, no. 1, p. 254–265, 2016, https://doi.org/10.1128/JVI.01720-15. Page 257,
Fig. 1D: The immunoﬂuorescence image of the 25 g/ml cGAMP-treated sample was
incorrect due to a labeling error in preparing the ﬁgure.
The 25 g/ml panel of Fig. 1D should appear as shown below.
The correction of the ﬁgure does not change the conclusions of the paper.
Citation Yi G, Wen Y, Shu C, Han Q, Konan KV,
Li P, Kao CC. 2018. Correction for Yi et al.,
“Hepatitis C virus NS4B can suppress STING
accumulation to evade innate immune
responses.” J Virol 92:e01520-17. https://doi
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